There were no clinically related changes compared to 2011 apart from new info and new recommendations with regards to the treatment method with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denosumab’). g., PARP inhibitor) being a consequence of knowledge on the use of PARP inhibitors in BRCA1/2 https://leopoldou853pyh0.blogscribble.com/profile